Comparison of the Clinical Efficacy of Anabolic Agents and Bisphosphonates in the Patients With Osteoporotic Vertebral Fracture: Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Neurospine

Date 2024 May 2

PMID 38697911

Authors

Ikchan Jeon

Sung Bae Park

Bong Ju Moon

Miyoung Choi

Sung Uk Kuh

Jongtae Kim

Affiliations

Soon will be listed here.

Abstract

Objective: We investigated the clinical efficacy of anabolic agents compared with bisphosphonates (BPs) for the incidence of new osteoporotic vertebral fracture (OVF) and fracture healing of OVF in the patients with OVF via meta-analyses of randomized controlled trials (RCTs).

Methods: Electronic databases, including PubMed, Embase, and Cochrane Library were searched for published RCTs till December 2022. The RCTs that recruited participants with osteoporosis at high-/very high-risk of fracture (a history of osteoporotic vertebral or hip fracture) or fresh OVF were included in this study. We assessed the risk of bias on every included RCTs, estimated relative risk (RR) for the incidence of new OVF and fracture healing of OVF, and overall certainty of evidence. Meta-analyses were performed by Cochrane review manager (RevMan) ver. 5.3. Cochrane risk of bias 2.0 and GRADEpro/GDT were applied for evaluating methodological quality and overall certainty of evidence, respectively.

Results: Five hundred eighteen studies were screened, and finally 6 eligible RCTs were included in the analysis. In the patients with prevalent OVF, anabolic agents significantly reduced the incidence of new OVF (teriparatide and romosozumab vs. alendronate and risedronate [RR, 0.57; 95% confidence interval, 0.45-0.71; p < 0.00001; high-certainty of evidence]; teriparatide vs. risedronate [RR, 0.50; 95% confidence interval, 0.37-0.68; p < 0.0001; high-certainty of evidence]). However, there was no evidence of teriparatide compared to alendronate in fracture healing of OVF (RR, 1.23; 95% confidence interval, 0.95-1.60; p = 0.12; low-certainty of evidence).

Conclusion: In the patients with prevalent OVF, anabolic agents showed a significant superiority for preventing new OVF than BPs, with no significant evidence for promoting fracture healing of OVF. However, considering small number of RCTs in this study, additional studies with large-scale data are required to obtain more robust evidences.

Citing Articles

A Real-Life Study in Sequential Therapy for Severe Menopausal Osteoporosis.

Sima O, Costachescu M, Stanciu M, Nistor C, Carsote M, Tanasescu D J Clin Med. 2025; 14(2).

PMID: 39860632 PMC: 11766421. DOI: 10.3390/jcm14020627.

Commentary on "Comparison of the Clinical Efficacy of Anabolic Agents and Bisphosphonates in the Patients With Osteoporotic Vertebral Fracture: Systematic Review and Meta-analysis of Randomized Controlled Trials".

Cho D Neurospine. 2024; 21(2):430-431.

PMID: 38955519 PMC: 11224746. DOI: 10.14245/ns.2448592.296.

From the Editor-in-Chief: Featured Articles in the June 2024 Issue.

Han I Neurospine. 2024; 21(2):373-374.

PMID: 38955514 PMC: 11224757. DOI: 10.14245/ns.2448600.300.

The Effects of Longer Use of Teriparatide on Clinical and Radiographic Outcomes after Spinal Fusion in Geriatric Patients.

Kim Y, Ha K, Bae H, Park H, Ko Y, Ko M Medicina (Kaunas). 2024; 60(6).

PMID: 38929563 PMC: 11205696. DOI: 10.3390/medicina60060946.

References

Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F . Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone. 2021; 154:116209. DOI: 10.1016/j.bone.2021.116209. View

Yamaguchi T, Sugimoto T, Yamauchi M, Matsumori Y, Tsutsumi M, Chihara K . Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J Bone Miner Metab. 2004; 23(1):36-40. DOI: 10.1007/s00774-004-0538-7. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Ballane G, Cauley J, Luckey M, El-Hajj Fuleihan G . Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int. 2017; 28(5):1531-1542. DOI: 10.1007/s00198-017-3909-3. View

Shi Z, Zhou H, Pan B, Lu L, Liu J, Kang Y . Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(12):e0168691. PMC: 5173248. DOI: 10.1371/journal.pone.0168691. View

Qaseem A, Forciea M, Denberg T, Barry M, Cooke M, Fitterman N . Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017; 166(11):818-839. DOI: 10.7326/M15-1361. View

Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S . Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490. PMC: 428525. DOI: 10.1136/bmj.328.7454.1490. View

Geusens P, Marin F, Kendler D, Russo L, Zerbini C, Minisola S . Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. J Bone Miner Res. 2018; 33(5):783-794. DOI: 10.1002/jbmr.3384. View

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

10.

McClung M, Wasnich R, Recker R, Cauley J, Chesnut 3rd C, Ensrud K . Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004; 19(1):11-8. DOI: 10.1359/JBMR.0301202. View

11.

Komatsubara S, Mori S, Mashiba T, Nonaka K, Seki A, Akiyama T . Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone. 2005; 36(4):678-87. DOI: 10.1016/j.bone.2005.02.002. View

12.

Komrakova M, Krischek C, Wicke M, Sehmisch S, Tezval M, Rohrberg M . Influence of intermittent administration of parathyroid hormone on muscle tissue and bone healing in orchiectomized rats or controls. J Endocrinol. 2011; 209(1):9-19. DOI: 10.1530/JOE-10-0353. View

13.

Hadji P, Zanchetta J, Russo L, Recknor C, Saag K, McKiernan F . The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2011; 23(8):2141-50. DOI: 10.1007/s00198-011-1856-y. View

14.

Canalis E, Giustina A, Bilezikian J . Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007; 357(9):905-16. DOI: 10.1056/NEJMra067395. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

16.

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020; 26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL. View

17.

Tsuchie H, Miyakoshi N, Kasukawa Y, Nishi T, Abe H, Segawa T . The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture. J Bone Miner Metab. 2015; 34(1):86-91. DOI: 10.1007/s00774-014-0646-y. View

18.

Aslan D, Andersen M, Gede L, de Franca T, Jorgensen S, Schwarz P . Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest. 2011; 72(1):14-22. DOI: 10.3109/00365513.2011.624631. View

19.

Brunkow M, Gardner J, Van Ness J, Paeper B, Kovacevich B, Proll S . Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68(3):577-89. PMC: 1274471. DOI: 10.1086/318811. View

20.

Yamaguchi T, Sugimoto T, Yamada H, Kanzawa M, Yano S, Yamauchi M . The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporos Int. 2002; 13(4):331-6. DOI: 10.1007/s001980200034. View